Integrin-Src-YAP1 signaling mediates the melanoma acquired resistance to MAPK and PI3K/mTOR dual targeted therapy

Activation of PI3K/AKT pathway is one of the most recurrent resistant mechanisms for BRAF-targeted therapy, and the combination of MAPK and PI3K/AKT inhibitors becomes one of the most promising regimens for BRAF-targeted relapsed melanoma patients. Although the potent drug efficacy was observed in p...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Chune, Zhang, Min, Song, Jinen, Zheng, Xiaobo, Xu, Guangchao, Bao, Yu, Lan, Jiang, Luo, Dan, Hu, Jianping, Li, Jingyi Jessica, Shi, Hubing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607431/
https://www.ncbi.nlm.nih.gov/pubmed/35006410
http://dx.doi.org/10.1186/s43556-020-00013-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607431/
https://www.ncbi.nlm.nih.gov/pubmed/35006410
http://dx.doi.org/10.1186/s43556-020-00013-0

Ejemplares similares